Eligible patients were early‐stage: 3639 (82.70%) were older than 55 years, 3835 (87.16%) were T1, 4209 (95.66%) were N0, 3963 (90.07%) did not receive chemotherapy The pathologic features of the majority of patients showed a low‐risk profile: 4270 (97.05%) were non‐triple negative breast cancer, 4217 (95.84%) were ER‐positive, 3879 (88.16%) were PR‐positive, and 4189 (95.20%) were HER2‐negative. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.